FindTrial
Sign In

Mivavotinib

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, Calithera Biosciences, Inc

Conditions

Advanced Malignant Solid NeoplasmNon-GCB/ABC Diffuse Large B-Cell LymphomaOvarian CarcinomaRefractory Malignant Solid NeoplasmRefractory Ovarian CarcinomaWith and Without MyD88 and/or CD79B Mutations

Phase 1

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
CompletedNCT03756818
M.D. Anderson Cancer CenterAdvanced Malignant Solid Neoplasm, Ovarian Carcinoma, Refractory Malignant Solid Neoplasm +1
Start: 2019-03-05End: 2023-02-23Updated: 2023-02-28

Phase 2

Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
TerminatedNCT05319028
Calithera Biosciences, IncNon-GCB/ABC Diffuse Large B-Cell Lymphoma, With and Without MyD88 and/or CD79B Mutations
Start: 2022-06-23End: 2023-02-24Updated: 2023-04-04

Related Papers

A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.
Journal of Clinical Oncology2024-06-011 citations
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
Cancer Medicine2024-03-016 citations
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
Oncotarget2023-01-265 citations
Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study
Blood2022-11-15